COMPANY

Welcome to Aprilbio

Intro

Aprilbio develops

diverse novel drugs based on
its own albumin binder
platform: SAFA™

Based on our human Fab antibody fragment technology, which specifically

binds to serum albumin, we develop drugs with enhanced efficacy,

half-life and adverse effect

Platform Technology

Selection and production of


candidate substances

01
SAFA
- Versatility
- Half-life Extension
02
HuDVFab Library
Endless Ab Source

Research & Development

Autoimmune/Autoinflammatory Disease
Anti-Cancer

Innovative & Diverse Pipelines
01
Autoimmune
Disease
(4 pipelines)
02
Anti-Cancer
(3 pipelines)

Business Strategy

Two-Track Strategy

01
Platform
Technology
- Applied to diverse MOA


and substances
- R&D Collaboration
02
Pipeline
- Licensing-Out to
global pharm
- Conduct clinical trial
- R&D Collaboration